Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with radiotherapy and temozolomide for newly diagnosed primary glioblastoma
NL-OMON27467Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in glioblastoma (GBM) and brain neoplasm, sponsored by Amsterdam University Medical Center. Primary endpoint: Safety. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)brain neoplasm
Beyond the preview
Go deeper on NL-OMON27467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27467.